Introduction
Cystic fibrosis (CF) is a genetic disease with multiple clinical manifestations, the most prevalent being pancreatic insufficiency with malnutrition and bronchiectasis with chronic airways infection; it is the latter that accounts for the greatest morbidity and the shortening of life, accounting for 85% of deaths in CF patients [1] . The natural history of the lung disease consists of early and persistent infection [2] , an exaggerated inflammatory response [3, 4] , and progressive airways obstruction, ultimately resulting in respiratory failure. As airways disease worsens, there is an increased likelihood of respiratory complications, such as pneumothorax, a well known complication of CF that was first reported in 1966 [5] . Our knowledge of spontaneous pneumothorax in patients with CF has increased in recent years; although there are no clinical trials of specific therapies, we rely on clinical experience of patients with spontaneous pneumothorax due to other lung diseases. What follows is a summary of our current knowledge of pneumothorax in CF patients.
Pathophysiology of cystic fibrosis lung disease
The pathogenesis of lung disease begins with gene mutations of the cystic fibrosis transmembrane conductance regulator (CFTR), a protein that normally resides in the apical surface of the airway epithelial cell. Pathogenic mutations result in either a reduction in or abnormal function of CFTR such that overall CFTR activity is markedly reduced [6] , thereby reducing CFTR's role in maintaining the airway surface liquid. The dehydrated airway surface liquid thus impairs ciliary function resulting in impaired mucociliary clearance [7] . Microaspiration allows entry of bacteria into the lower airways and these opportunists expand in numbers to create chronic infection. Pseudomonas aeruginosa is the most commonly cultured pathogen from the CF airways, but others, notably Staphylococcus aureus, Haemophilus influenzae, Achromobacter, Stenotrophomonas, and Burkholderia are isolated frequently [1] . Although standard culture techniques reveal one to three pathogens, recent evidence suggests that many more opportunistic bacterial species also may be present in chronic airway infections [8] .
The chronic infection of the airways is met with an exaggerated inflammatory response [4] . Thus, the secretions present in the CF airways contain pathogenic bacteria, inflammatory cells, and inflammatory cytokines that recruit new inflammatory cells. It is the persistent inflammation that causes injury to the airways, ultimately leading to structural airway changes Purpose of review Cystic fibrosis (CF) is a complex genetic disease affecting many organs, although 85% of the mortality is a result of lung disease. The natural history of the lung disease consists of early and persistent infection, an exaggerated inflammatory response, structural airway changes (i.e. bronchiectasis), and progressive airways obstruction, ultimately resulting in respiratory failure. As airways disease worsens, there is an increased likelihood of respiratory complications, such as pneumothorax, that may be serious. This review describes our current understanding of the pathogenesis of pneumothorax in CF and its treatment.
Recent findings
The CF Foundation Pulmonary Therapies Committee recently published their recommendations for the treatment of hemoptysis and pneumothorax. As insufficient data exist from which a systematic review of the literature could be used to develop guidelines, the recommendations were derived from a formalized expert panel consensus process.
Summary
We now have recommendations on specific care of the patient with CF who has a pneumothorax. (i.e. bronchiectasis). The patient suffers daily symptoms of chronic airways infection, including cough productive of purulent sputum, and there are also episodes of acute worsening of respiratory symptoms often referred to as pulmonary exacerbations. The natural history of the disease is one of progressive airways obstruction ultimately resulting in respiratory failure.
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Epidemiology of pneumothorax in cystic fibrosis
Spontaneous pneumothorax occurs relatively commonly in patients with CF; approximately 3.4% of all patients will suffer this complication during their lifetime [9] . The average annual incidence of pneumothorax in CF is 0.64%, or 1 in 167 patients per year [9] . Recurrent pneumothorax, defined as a pneumothorax that develops on the ipsilateral side more than 7 days after the resolution of the initial pneumothorax, is also common, occurring in an estimated 50-90% of patients [10] ; there is also a high rate (46%) of subsequent contralateral pneumothorax [11] .
The most recent analysis of a CF patient registry found that the median age for pneumothorax is 21 years, and most (72.4%) occur in adults ( Fig. 1) [9] . Pneumothorax is most commonly associated with severe obstructive airways impairment with 75% of pneumothoraces occurring in patients with an FEV 1 less than 40% of predicted ( Fig. 2) [9] . The analysis also found other factors associated with pneumothorax, some of which could be assumed to be part of the pathophysiology (Table 1) .
Pathophysiology of pneumothorax in cystic fibrosis
The pathophysiology of pneumothorax in CF patients is similar to that of other lung diseases with spontaneous pneumothorax (e.g. lymphangioleiomyomatosis). Because patients typically have severe obstructive airways disease, plugging of the distal airways with thick secretions may result in trapping of air within the alveoli. When alveolar pressure exceeds interstitial pressure, air moves into the interstitium, travels along the airways into the hilum (pneumomediastinum), and ruptures into the mediastinal parietal pleura. High-resolution computed tomography (HRCT) of the chest has demonstrated air-trapping at end-expiration in non-CF patients with spontaneous pneumothorax, consistent with the notion that air trapping is part of the pathogenesis of this complication [12] . Air-trapping has also been reported in CF patients with pneumothorax, as demonstrated by an increase in residual volume [13, 14] . An alternate mechanism of pneumothorax is by rupture of subpleural blebs on the visceral pleura, but this is less common and Pneumothorax in cystic fibrosis Flume 221
Key points
Pneumothorax is a common complication that occurs in cystic fibrosis (CF) patients with severe obstructive airways disease. Consensus guidelines have been published regarding the management of pneumothorax in the CF patient.
The use of aerosolized medications and airway clearance therapies may need to be altered in the patient with cystic fibrosis and a pneumothorax. Nearly three-fourths of patients have their first episode after the age of 18 years. Adapted from [9] . Most pneumothoraces occur in patients with severe obstructive impairment. pred, predicted. Data derived from [9] .
there is a poor correlation between the presence of blebs or cysts and pneumothorax in the CF population [15] .
Other factors identified to be associated with pneumothorax in CF (Table 1) include the presence of Pseudomonas or Burkholderia in the airways, which are well known to be associated with progressive decline in lung function. Interestingly, Staphylococcus was associated with a lower risk of pneumothorax. There is recent evident that this pathogen may also be associated with progression of lung disease [16] . Allergic bronchopulmonary aspergillosis (ABPA) is an asthma-like complication that may result in increased air-trapping and there is a greater prevalence of ABPA in patients with CF [17] . Aspergillus is typically considered a colonizer of the CF airways and not necessarily a pathogen [18] . The presence of Aspergillus in sputum cultures alone is not sufficient to make the diagnosis of ABPA, and far more CF patients have Aspergillus in the sputum than have ABPA. Therefore, there may be other factors associated with Aspergillus that suggest it is a true pathogen and not merely a colonizer [19, 20] .
The aerosolized medications dornase alfa and tobramycin are associated with an increased risk of pneumothorax (Table 1) . A potential explanation for this association may be related to bronchospasm with an acute decrease in FEV 1 that can occur in some patients following inhalation of medications [21] .
An important risk factor known to be associated with spontaneous pneumothorax in other disease is smoking tobacco [22, 23] . The estimated prevalence of smoking in CF patients is 8-21% [24, 25] , but there are no reported cases of pneumothorax in a CF patient who is also a smoker.
Diagnosis of pneumothorax in cystic fibrosis
The typical presentation is acute onset of chest pain and breathlessness, and the diagnosis is confirmed by chest Xray (CXR) [26 ] . However, there may be unusual cases in which a CXR will not provide the diagnosis. Patients with CF may have pleural adhesions that prevent collapse of the lung away from the chest wall. Therefore, the pneumothorax may not be apparent on CXR and chest tomography may be needed to make the diagnosis (Fig. 3 ) [26 ,27] .
Management of pneumothorax in cystic fibrosis
There are no clinical trials to guide proper therapy of pneumothorax in CF patients. The literature consists primarily of retrospective reports of clinical experience. There were two recently published guidelines on the management of pneumothorax, the British Thoracic Society guidelines for all cases of spontaneous pneumothorax [26 ] and a CF-specific set of consensus recommendations from a panel of experts in CF care [27] . Factors that may affect treatment decisions include the size of the pneumothorax, severity of disease, stability of the patient, and whether this is the first or a recurrent pneumothorax. For the purposes of the consensus guidelines the size of a pneumothorax was either small (<5 cm) or large (>5 cm). In general, the size of the pneumothorax is less important than the degree of clinical compromise [26 ] .
Many patients who have small pneumothoraces may be managed in the outpatient setting whereas all patients with a large pneumothorax should be admitted to the hospital [26 ,28 ] . The expert panel felt that small pneumothoraces may be treated by either observation or small catheter aspiration unless the patient is unstable. Although this approach has been previously reported to result in failure in the patient with CF [29, 30] , a recent review of CF-related pneumothoraces in Scotland reported a high rate of success [31] . The large pneumothorax is treated by placement of a chest tube for evacuation of the pleural space. The reported rate of treatment failure with chest tube drainage alone is estimated to be 37% and given a high rate of recurrence, it is estimated that 70% of patients may ultimately require more definitive treatment (i.e. pleurodesis) [10] . Nonetheless, the recommendations are to reserve pleurodesis for recurrent large pneumothoraces. There are no trials comparing chemical to surgical pleurodesis [32] . However, it is thought that surgical pleurodesis appears to be the most effective and preferred treatment, but if the patient is unable to tolerate surgery, chemical pleurodesis (e.g. talc) should be performed [26 ] . Although contralateral pneumothorax is common, prophylactic plerodesis on the opposite side is not considered standard therapy.
The normal daily treatment of CF lung disease involves performance of airway clearance therapies [33 ] and a number of inhaled medications to maintain lung health [34] . Some patients with advanced stage disease may also be on noninvasive ventilatory support [e.g. bilevel positive airway pressure (BiPAP) ventilation] [35] . The delivery of these therapies in the patient with a pneumothorax could aggravate the complication or contribute to the patient's pain.
There are many methods of assisting clearance of airway secretions including percussion and postural drainage, active cycle breathing technique (ACBT), autogenic drainage, positive expiratory pressure (PEP), oscillating PEP (oPEP), intermittent percussive ventilation (IPV), and high-frequency chest compression [33 ] . These therapies are performed on a daily basis by patients to reduce the accumulation of inflammatory and infectious airway secretions. In general, the expert panel did not recommend stopping airway clearance therapies in patients with a small pneumothorax with the exception of IPV, PEP, and oPEP therapies. This is because of the theoretical concern that positive pressure associated with these therapies might worsen the pneumothorax. For the patient with a large pneumothorax, the recommendation was to withhold airway clearance for all patients, although there was no consensus for ACBT or autogenic drainage, which might be considered gentler forms of therapy that should not exacerbate the pneumothorax or pain.
Aerosolized medications are commonly used as chronic therapy. Dornase alfa and inhaled tobramycin have been identified as having an association with pneumothorax (Table 1) , although causality has not been determined [9] . As stated earlier, it is conceivable that inhaled medications can cause bronchospasm [21] , which could worsen or cause a pneumothorax. Nonetheless, the expert panel did not recommend withholding any aerosol medications for either a small or large pneumothorax [28 ] . There was somewhat greater concern about hypertonic saline because of its ability to cause cough [36] but not so much as to recommend withholding it.
Additional recommendations were to withhold, if possible, BiPAP for patients with any size pneumothorax, at least until the pneumothorax has resolved [28 ] . This is to prevent any expansion of the pneumothorax or prevention of its resolution. They also recommended restriction of specific activities for at least 2 weeks following resolution of the pneumothorax including flying, lifting weights and performance of spirometry [28 ] . However, they did not recommend withholding aerobic exercise, which has been recommended as an adjunct to airway clearance therapy [33 ] .
After resolution of the pneumothorax, the clinician may want to consider those factors associated with pneumothorax as this could influence management. Given the association of pneumothorax with ABPA, all patients should be evaluated for this diagnosis as this may lead to treatment with steroids or other therapies [37] . Inhaled or systemic corticosteroids are not recommended as a routine therapy for CF patients, but this recommendation excludes those patients with concomitant ABPA [34] . Also, noting the association of pneumothorax with certain inhaled medications, an assessment of airway reactivity to inhaled medications in patients with more severe lung impairment (e.g. FEV 1 <50% of predicted) should be considered.
Outcomes of pneumothorax in cystic fibrosis
The pneumothorax causes pain and shortness of breath, and has an adverse effect on overall lung function [10] . It is associated with high healthcare costs with increased visits, hospitalizations, and hospital days [9] . Some patients will die acutely as a result of pneumothorax, with an attributable mortality estimated at 6.3-14.3%, and it also may be a prognostic factor as the 2-year mortality rate in patients following a pneumothorax is high (48.6%) [9] . Despite this, the expert panel did not feel that pneumothorax alone is sufficient to warrant referral of a patient for lung transplant. For those patients who may be referred for lung transplantation, previous pleurodesis is not an absolute contraindication to lung transplantation [38] .
Conclusion
Chronic infection and inflammation is a cardinal manifestation of CF airways disease. The disease is progressive causing worsening obstruction of the airways. The patient is vulnerable to a spontaneous pneumothorax, particularly when the stage of disease becomes severe. There are known factors associated with pneumothorax in CF and the clinician can try to address these risk factors in the hopes of reducing the risk of pneumothorax. We now have treatment guidelines to assist with the management of pneumothorax in CF. The clinician should be able to recognize and manage these complications, as well as understand the implications of these complications in the long-term planning in the care of patients with CF.
